Plerixafor in poor stem cell mobilizers: The Belgian compassionate use program

Acta Clinica Belgica

Volumn 66, Issue 3, 2011, Pages 200-204

  Selleslag, D ^a   Dierickx, D ^b   Breems, D A ^c   Huynh, P ^d   Van De Velde, A ^e   Meers, S ^b   Brouwer, E ^f   Mertens, A ^f  

^a AZ Sint Jan Brugge Oostende ^*  (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ZiekenhuisNetwerk Antwerpen   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f Genzyme Belgium NV/SA   (Belgium)

Author keywords

Compassionate use program; Hodgkin's lymphoma; Multiple myeloma; Non Hodgkin's lymphoma; Plerixafor; Poor mobilizers

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34 SELECTION; CLINICAL ARTICLE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; STEM CELL MOBILIZATION; THROMBOCYTE;

ANTIGENS, CD34; CELL COUNT; COMPASSIONATE USE TRIALS; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; RECEPTORS, CXCR4;

EID: 79960986648     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.3.2062547     Document Type: Article

References (14)

1. Harousseau JL, Dreyling M. ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(S2): ii55-ii57.
2. Smith A, Wisloff F, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410-451.
3. Barosi G, Carella A, Lazzarino M, et al. Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91: 96-103. (Pubitemid 43235392)
4. Tilly H, Dreyling M; ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(S2): ii67-69.
5. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
6. Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-842. (Pubitemid 32496417)
7. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamäki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colonystimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-351. (Pubitemid 36410680)
8. Petrucci MT, Avvisati G, La Verde G, et al. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Acta Haematol 2003; 109: 184-188. (Pubitemid 36829016)
9. Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 2007; 47: 629-635. (Pubitemid 46449623)
10. Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-282. (Pubitemid 30045370)
11. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
12. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
13. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
14. Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 64: 52-58.